Prohibitin-targeting peptide 1

{{Infobox drug

| drug_name =

| INN =

| type =

| image =

| alt =

| caption =

| pronounce =

| tradename = Adipotide

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_US =

| pregnancy_category=

| routes_of_administration =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_DE =

| legal_NZ =

| legal_UK =

| legal_US =

| legal_UN =

| legal_status = Investigational

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| IUPAC_name =

| CAS_number = 859216-15-2

| PubChem =

| DrugBank =

| synonyms = Prohibitin-TP01; TP01

| chemical_formula =

| molecular_weight =

}}

Prohibitin-targeting peptide 1 (also known as prohibitin-TP01 and TP01; trade name Adipotide) is a peptidomimetic with sequence CKGGRAKDC-GG-_D(KLAKLAK)₂. It is an experimental proapoptotic drug{{Cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prohibitin-targeting-peptide-1 | title = Prohibitin-targeting peptide 1 | work = NCI Drug Dictionary | date = 2 February 2011 | publisher = National Cancer Institutes }} that has been shown to cause rapid weight loss in mice{{cite journal | vauthors = Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W | title = Reversal of obesity by targeted ablation of adipose tissue | journal = Nature Medicine | volume = 10 | issue = 6 | pages = 625–32 | date = June 2004 | pmid = 15133506 | doi = 10.1038/nm1048 | publisher = Nature Publishing Group | s2cid = 19369938 }} and rhesus monkeys.{{cite web |url=http://medicalxpress.com/news/2011-10-blood-vessel-reveals-codes.html |title=Blood vessel mapping reveals four new 'ZIP codes' |date=24 October 2011 |publisher=medicalxpress |access-date=10 November 2011}} Its mechanism of action is to target specific blood vessels supplying adipose tissue with blood, cause the vessels to shrink and the fat cells fed by those vessels to undergo apoptosis.{{cite journal | vauthors = Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R | display-authors = 6 | title = A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys | journal = Science Translational Medicine | volume = 3 | issue = 108 | pages = 108ra112 | date = November 2011 | pmid = 22072637 | pmc = 3666164 | doi = 10.1126/scitranslmed.3002621 }} TP01 is designed to bind to two receptors, ANXA2 and prohibitin, that are specific to blood vessels supplying white adipose tissue.{{cite journal | vauthors = Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W | display-authors = 6 | title = Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 108 | issue = 46 | pages = 18637–42 | date = November 2011 | pmid = 22049339 | pmc = 3219136 | doi = 10.1073/pnas.1114503108 | bibcode = 2011PNAS..10818637S | doi-access = free }}

As of 2019, clinical development has been discontinued.{{Cite web | url = https://adisinsight.springer.com/drugs/800035229 | title = Prohibitin targeting peptide 1 | work = Adis Insight | publisher = Springer Nature Switzerland AG }}